April 11, 2025 | Shanghai & Cambridge, MA — SIMR Biotech announced today that its abstract titled “Targeting Lp-PLA2: A Novel Therapeutic Approach for Diabetic Kidney Disease” has been accepted for poster presentation at the 85th American Diabetes Association (ADA) Scientific Sessions, taking place June 20-24, 2025 in Chicago, Illinois.
The presentation will feature preclinical and early clinical data on SR1375, a first-in-class oral Lp-PLA2 inhibitor, demonstrating its ability to modulate renal inflammation, preserve endothelial function, and protect parenchymal cells in the context of diabetic nephropathy.
“Being selected to present at ADA reflects the growing recognition of SR1375’ s differentiated approach in addressing the inflammatory drivers of diabetic kidney disease,” said Dr. Li Shuai, Founder and CEO of SIMR Biotech. “We believe targeting Lp-PLA2 opens a new chapter in DKD treatment innovation.”
ADA 2025 Poster Presentation Highlights:
Title: Targeting Lp-PLA2: A Novel Therapeutic Approach for Diabetic Kidney Disease
Session Type: Poster Presentation
Conference: 85th ADA Scientific Sessions
Date: June 20 - 24, 2025
Location: McCormick Place, Chicago, IL
About SR1375:
SR1375 is a first-in-class small molecule inhibitor of Lp-PLA2, a key enzyme implicated in chronic vascular inflammation and end-organ damage in diabetic complications. Its dual action on immune cell infiltration and epithelial protection positions it as a promising candidate for disease-modifying therapy in DKD. SR1375 has already obtained IND approval for DKD in China NMPA and is currently under preclinical studies and IND-enabling research for additional cardiorenal indications.
